We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

RPA-LF Assay Evaluated for Cutaneous Leishmaniasis in Colombia

By LabMedica International staff writers
Posted on 17 May 2021
Image: Results of the Recombinase Polymerase Amplification-Lateral Flow (RPA-LF) assay for cutaneous leishmaniasis (Photo courtesy of University of Texas Medical Branch)
Image: Results of the Recombinase Polymerase Amplification-Lateral Flow (RPA-LF) assay for cutaneous leishmaniasis (Photo courtesy of University of Texas Medical Branch)
Cutaneous leishmaniasis (CL) is a recognized public health challenge in the Americas, with an average of 55,000 cases per year between 2001 and 2018 in 17 countries of the region. Most cases (79.4%) have been acquired in and continue to occur in rural areas.

Currently available diagnostic methods for CL have several limitations. Light microscopic analysis of smears obtained from cutaneous lesions is the most commonly used diagnostic method for CL because of its low cost, yet its sensitivity varies widely depending on the experience and skill of the operator. In addition, sensitivity of microscopy is diminished in lesions of longer duration in chronic lesions with their notorious low parasite burden.

A team of tropical medicine specialists from the University of Texas Medical Branch (Galveston, TX, USA) and the Universidad Icesi (Cali, Colombia) conducted a cross-sectional study of diagnostic test performance between January 2018 and July 2019. There were 118 participants ≥2 years of age, with ulcerated skin lesions of more than two weeks’ duration were eligible and enrolled consecutively either in their residence (in rural Tumaco) by community health workers, or when seeking care at the primary health facility in urban Tumaco or the reference center laboratory in Cali.

The team utilized a composite “gold standard” based on microscopy of lesion smear, culture, histopathology of biopsy and qPCR18S as a reference. Minimally invasive swab and FTA filter paper samples were obtained by community health workers and highly trained technicians from ulcerated lesions. The investigators evaluated the diagnostic test performance of Isothermal Recombinase Polymerase Amplification (RPA) targeting Leishmania kinetoplast DNA, coupled with a lateral flow (LF) immunochromatographic strip, in a field setting and a laboratory reference center.

The scientists reported that the sensitivity and specificity of RPA-LF in the reference lab scenario were 87% (95%CI 74–94) and 86% (95%CI 74–97), respectively. In the field scenario, the sensitivity was 75% (95%CI 65–84) and specificity 89% (95%CI 78–99). Positive likelihood ratios in both scenarios were higher than six while negative likelihood ratios ranged to 0.2–0.3 supporting the usefulness of RPA-LF to rule-in and potentially to rule-out infection.

The authors concluded that RPA-LF is a valid, efficacious test to diagnose CL that could replace or complement microscopy in rural areas. Its combination with non-invasive sampling and low complexity requirements for processing and interpreting results position this test as an achievable alternative for diagnosis of CL at points of care in Colombia. The study was published on April 28, 2021 in the journal PLOS Neglected Tropical Diseases.


Related Links:
University of Texas Medical Branch
Universidad Icesi


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®

Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more